Topics
Products
-
Wednesday - February 17, 2010
Conductive nano inks for printed electronics
Aiming for cost-effective, reproducible production of flexible circuits » more
-
Wednesday - February 17, 2010
New product grade: Baytubes® C 70 P
Carbon nanotubes with improved dispersibility » more
-
Sunday - December 6, 2009
Treatment of Venous Thromboembolism (VTE):
Phase III EINSTEIN-Extension Study of Bayer’s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
Impressive 82% Relative Risk Reduction (RRR) in the Recurrence of Symptomatic VTE over Patients Treated with Placebo / Positive Benefit-Risk profile for Rivaroxaban Confirmed / First Phase III Data in the Chronic Setting to be Presented as a Late-Breaker at the Annual Meeting of the American Society of Hematology / Ongoing Discussions with FDA on Complete Response Letter for VTE Prevention After Total Knee and Hip Replacement Surgery » more
-
Tuesday - December 1, 2009
Bayer’s Betaferon® approved in China for Treatment of Multiple Sclerosis
Launch planned by mid 2010 » more
-
Thursday - November 26, 2009
Multitec® Flex polyurethane spray system from BaySystems proves effective in theater
Long-lasting protection for stage sets
Cost-effective solution for Milan´s La Scala opera house » more
-
Thursday - November 19, 2009
Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE » more
-
Friday - October 23, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer » more
-
Thursday - October 8, 2009
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy » more
-
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany » more
-
Wednesday - August 19, 2009
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction » more
-
Wednesday - July 22, 2009
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies » more
-
Wednesday - July 22, 2009
Pharmaceutical quality acetonitrile
Bayer Technology Services has developed a purification process for acetonitrile
Conventional product can be purified for 10 to 17 euros per liter ACN. » more
-
Tuesday - June 30, 2009
Bayer MaterialScience invests in innovative technology for the future
Unique expertise in automotive polycarbonate glazing
New two-component injection molding machine paves the way for further technology enhancements and even better customer service / Rear windows a further focus of development / High-performance coating pilot plant integrated in the BayVision® concept » more
-
Tuesday - June 30, 2009
New injection molding system as an innovation platform for technology, application and material development
Film insert molding for large glazing applications with polycarbonate
Excellent molded part quality thanks to adapted process and mold technology » more
-
Monday - June 15, 2009
New film enables production of unmistakable, unique IDs
Cards stacked against counterfeiters
Excellent potential also for logistics, brand protection and labeling » more
-
Monday - June 1, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer » more
-
Thursday - May 28, 2009
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
U.S. FDA Issues Complete Response Letter for Rivaroxaban
No new clinical or non-clinical studies to be conducted as a pre-requisite for approval » more
-
Friday - May 22, 2009
45th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506 » more
-
Wednesday - May 20, 2009
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer » more
-
Friday - May 15, 2009
Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting » more
Search
Publications
Annual Report
Stockholders' Newsletter
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
Events
Download Center - Selection